DAXXIFY
Live / Registered — Registered (as of 17 Jun 2025)
What this means for you
Registered since 17 Jun 2025. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 17 Jun 2031: the §8 declaration of use).
Record
- Serial number
- 97809052
- Registration number
- 7836568
- Mark type
- Word mark
- Filed
- 23 Feb 2023
- Published for opposition
- 02 Jan 2024
- Registered
- 17 Jun 2025
- Next maintenance filing
- §8 declaration of use, due by 17 Jun 2031 (grace period to 17 Dec 2031)
- Attorney of record
- Jennifer Waitman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, muscle spasms, and pain; pharmaceutical preparations, namely, peptide substrates for use in the treatment of neurological disorders, muscle dystonias, muscle spasms, and pain
Owner
- Revance Therapeutics, Inc., GLENGORMLEY, DE, GB
- Revance Therapeutics, Inc., Newark, CA
- Revance Therapeutics, Inc., Newark, CA
Prior registrations
Prosecution history
- 20 Jan 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 20 Jan 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 20 Jan 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Aug 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 04 Aug 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 04 Aug 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Aug 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 04 Aug 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 17 Jun 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 17 Jun 2025 — REGISTERED-PRINCIPAL REGISTER
- 23 May 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 23 May 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 12 May 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 20 Feb 2025 — USE AMENDMENT FILED
- 09 May 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL